Browse the corpus

Liposarcoma is the most common soft-tissue sarcoma in adults, accounting for approximately 20% of cases and arising most often in the extremities and retroperitoneum. This course outlines the 4 histologic subtypes recognized by the World Health Organization—well-differentiated, dedifferentiated, myxoid, and pleomorphic—and their characteristic features, as each is defined by distinct molecular alterations, clinical behavior, and treatment response. The recommended diagnostic evaluation for liposarcomas, which relies on cross-sectional imaging and image-guided core needle biopsy, is also discussed. This activity reviews liposarcoma pathogenesis, clinical presentation, interpretation of diagnostic evaluation findings, prognosis, and management strategies, including complete surgical resection with negative margins and radiation and systemic treatments selected based on tumor grade, location, and subtype. Participants will also gain an understanding of appropriate imaging selection, biopsy techniques, molecular diagnostics, staging, and interprofessional treatment planning. This activity for healthcare professionals is designed to enhance the learner's competence in identifying liposarcomas, recognizing red-flag symptoms, understanding subtype-specific therapeutic considerations, determining prognostic factors to support accurate diagnosis, ensuring timely referral, optimizing patient-centered care across clinical settings, and implementing an appropriate interprofessional approach when managing this condition. Objectives: Identify the histologic characteristics of liposarcoma that influence treatment decisions. Apply evidence-based imaging techniques to ensure accurate staging of suspected liposarcoma. Evaluate tumor features to determine appropriate therapeutic strategies. Collaborate with interprofessional teams to coordinate patient-centered care and optimize treatment outcomes in patients with liposarcomas. Access free multiple choice questions on this topic.

Liposarcoma is the most common soft-tissue sarcoma in adults, accounting for approximately 20% of all soft-tissue sarcomas. These malignant tumors arise predominantly in the extremities (52%) and retroperitoneum (19%) but may develop in any anatomic location containing adipose tissue. The World Health Organization (WHO) classifies liposarcoma into 4 distinct histologic subtypes: well-differentiated, dedifferentiated, myxoid, and pleomorphic. Each subtype exhibits unique molecular alterations, clinical behaviors, and treatment responses, with well-differentiated liposarcoma representing the most frequently encountered subtype.[1][2][3][2] Accurate diagnosis requires image-guided core needle biopsy for histologic confirmation. Magnetic resonance imaging (MRI) provides optimal evaluation for extremity lesions, while computed tomography (CT) is preferred for retroperitoneal tumors. Staging involves cross-sectional imaging of the chest, abdomen, and pelvis to assess for metastatic disease. Complete surgical resection with negative margins forms the foundation of curative treatment. Radiation therapy is often used as a neoadjuvant or adjuvant intervention to enhance local control, particularly in high-grade extremity tumors. Systemic chemotherapy demonstrates variable efficacy depending on histologic subtype, with myxoid liposarcoma showing notable chemosensitivity and well-differentiated liposarcoma remaining largely resistant. Prognosis depends on histologic subtype, tumor grade, anatomic location, and margin status. This activity reviews the evaluation and management of liposarcoma, with emphasis on extremity disease. Please see StatPearls' companion resource, "Retroperitoneal Liposarcoma," for further information on nonextremity tumors.

The etiology of liposarcoma involves complex genetic alterations, with distinct chromosomal abnormalities accounting for more than 90% of cases. Well-differentiated and dedifferentiated liposarcomas demonstrate characteristic amplification of the MDM2 and CDK4 genes in over 90% of cases, resulting in chromosome 12q13-15 amplifications manifesting as supernumerary ring chromosomes or giant marker chromosomes.[4] These genetic alterations result in the overexpression of the MDM2 protein, which inhibits the p53 tumor suppressor pathway, thereby promoting cell cycle progression and preventing apoptosis. Myxoid liposarcomas exhibit a distinct molecular pathogenesis characterized by the t(12;16)(q13;p11) translocation in approximately 95% of cases, resulting in the FUS-DDIT3 fusion gene, or less commonly, the t(12;22)(q13;q12) translocation, which produces the EWSR1-DDIT3 fusion gene. These fusion proteins disrupt normal adipocytic differentiation and drive tumorigenesis. Pleomorphic liposarcoma lacks characteristic molecular markers and demonstrates complex karyotypes with multiple chromosomal aberrations.[5] Furthermore, environmental and occupational risk factors have been implicated in the development of soft tissue sarcoma. Occupational exposure to chlorophenols, phenoxyacetic acid herbicides, including Agent Orange, and dioxins has been associated with increased sarcoma risk in epidemiologic studies, particularly among agricultural workers and Vietnam War veterans. The relative risk increase remains modest, estimated to be 1.2 to 2.0 times higher in exposed populations.[6] Prior therapeutic radiation exposure represents a well-established risk factor for secondary sarcoma development, with latency periods typically ranging from 8 to 20 years postirradiation. The absolute risk remains below 1% for most patients receiving radiation therapy, with cumulative doses exceeding 50 Gy conferring a higher risk. Radiation-associated sarcomas tend to be high-grade and carry worse prognoses compared to spontaneous tumors.[6][7]

Furthermore, environmental and occupational risk factors have been implicated in the development of soft tissue sarcoma. Occupational exposure to chlorophenols, phenoxyacetic acid herbicides, including Agent Orange, and dioxins has been associated with increased sarcoma risk in epidemiologic studies, particularly among agricultural workers and Vietnam War veterans. The relative risk increase remains modest, estimated to be 1.2 to 2.0 times higher in exposed populations.[6] Prior therapeutic radiation exposure represents a well-established risk factor for secondary sarcoma development, with latency periods typically ranging from 8 to 20 years postirradiation. The absolute risk remains below 1% for most patients receiving radiation therapy, with cumulative doses exceeding 50 Gy conferring a higher risk. Radiation-associated sarcomas tend to be high-grade and carry worse prognoses compared to spontaneous tumors.[6][7] Additionally, hereditary cancer predisposition syndromes account for a small fraction of liposarcomas. Li-Fraumeni syndrome, caused by germline TP53 mutations, significantly increases the risk of developing soft tissue sarcoma, with affected individuals having a 50% lifetime probability of developing this type of cancer. Neurofibromatosis type 1 patients show increased risk for malignant peripheral nerve sheath tumors, but not specifically liposarcomas. Retinoblastoma survivors with germline RB1 mutations face elevated secondary sarcoma risk following radiation therapy. The vast majority of liposarcomas occur sporadically without an identifiable hereditary predisposition, and routine genetic counseling is not indicated unless clinical features suggest an underlying syndrome.[8]

Liposarcoma ranks among the most common malignant soft-tissue sarcomas, accounting for 15% to 20% of adult soft-tissue sarcomas in the United States and globally. The annual incidence approximates 2.5 cases per million, with rates remaining stable across high-income countries, although variations may influence international comparisons in diagnostic practices and reporting. Peak incidence occurs between ages 50 and 65, while pediatric and adolescent cases remain rare, accounting for less than 5% of diagnoses. Well-differentiated and dedifferentiated subtypes predominantly present in older adults, typically in retroperitoneal locations. Myxoid liposarcoma commonly affects patients younger than 50, most frequently in the extremities, particularly the thigh. Pleomorphic liposarcoma, the rarest subtype, primarily affects adults aged 60 or older.[9] Liposarcoma demonstrates a slight male predominance, with a male-to-female ratio of approximately 1.2 to 1.5:1, consistent across subtypes and anatomical locations. When adjusting for healthcare access and socioeconomic factors, racial and ethnic differences remain minimal, with comparable incidence across populations in the United States. Anatomically, the extremities account for 52% of cases, followed by the retroperitoneum (19%), trunk (18%), and head and neck (9%). Retroperitoneal tumors are mostly well-differentiated or dedifferentiated, representing 70% to 80% of cases, whereas myxoid and pleomorphic tumors primarily involve the extremities. Rare sites, including the mediastinum and abdominal viscera, represent less than 2% of cases. The 5-year survival varies by subtype, grade, location, and surgical margin status. Well-differentiated liposarcoma survival rates exceed 95% when completely resected, dedifferentiated liposarcoma ranges from 50% to 70%, myxoid liposarcoma from 70% to 80%, and high-grade round cell or pleomorphic variants from 30% to 50%. Retroperitoneal tumors often carry poorer outcomes due to challenges in achieving negative margins and higher rates of local recurrence.[9][10]

Liposarcoma's pathophysiology is characterized by disrupted adipocyte differentiation and uncontrolled cell proliferation, driven by specific genetic alterations associated with various histological subtypes. These changes result in differences in clinical behavior, including tumor growth patterns, metastatic potential, and treatment responses. This understanding is vital for surgical planning, therapeutic decisions, and the prediction of disease progression. Well-differentiated and dedifferentiated liposarcomas arise from amplification of the MDM2 and CDK4 genes, leading to inactivation of the p53 pathway and disruptions to the cell cycle. Well-differentiated tumors grow slowly, often reaching 10 to 30 cm in diameter before detection, as they typically cause no symptoms. Well-differentiated liposarcoma often infiltrates along fascial planes and does not reliably respect fascial boundaries, especially in the retroperitoneum. Although they usually don't metastasize, local recurrence happens in 40% to 60% of retroperitoneal cases and 10% to 30% of extremity tumors. About 10% to 15% of well-differentiated tumors may dedifferentiate over time, evolving into a more aggressive form that requires wider surgical margins and may need systemic therapy.[11][12] Myxoid liposarcoma arises from FUS-DDIT3 or EWSR1-DDIT3 fusion genes, resulting in disrupted adipocyte maturation. These tumors have intermediate growth rates, with multifocal disease occurring in less than 5% of cases and a unique tendency to metastasize to soft tissue, bone, and retroperitoneum rather than the lungs. Imaging strategies must account for this unusual pattern, employing whole-body scans for comprehensive staging. High-grade round cell components indicate aggressive disease with rapid growth and a poor response to chemotherapy, though myxoid components are generally more treatable. Radiation therapy can also significantly reduce tumor size and improve local control.[13] Pleomorphic liposarcoma exhibits complex genetic alterations that contribute to its aggressive behavior. These tumors proliferate, often exceeding 10 cm, and have high metastatic rates (30%-50%), primarily to the lungs. They often invade neurovascular structures, complicating surgical resection and frequently necessitating vascular reconstruction or nerve grafting.

Pleomorphic liposarcoma exhibits complex genetic alterations that contribute to its aggressive behavior. These tumors proliferate, often exceeding 10 cm, and have high metastatic rates (30%-50%), primarily to the lungs. They often invade neurovascular structures, complicating surgical resection and frequently necessitating vascular reconstruction or nerve grafting. The pathophysiological implications extend to the timing of symptom development. Large retroperitoneal tumors may grow unnoticed until they cause nonspecific symptoms, such as abdominal distension or early satiety. Extremity tumors often manifest as pain or functional impairment due to neurovascular compression. High-grade tumors may present systemic symptoms like fatigue and weight loss, indicating aggressive disease. The location affects surgical complexity; retroperitoneal tumors may encase major vessels, requiring extensive surgery, while extremity tumors might necessitate sacrificing nerves or vessels for clear margins.

Liposarcoma comprises 4 major histologic subtypes, each characterized by unique microscopic features, immunohistochemical profiles, and molecular alterations that are crucial for diagnosis, prognosis, and treatment planning.[14] Well-Differentiated Liposarcoma Well-differentiated liposarcomas are the most common subtype, accounting for 40% to 45% of all liposarcomas. Microscopic examination reveals mature adipocytes with variations in cell size (lipoma-like variant), scattered atypical stromal cells with hyperchromatic nuclei, and lipoblasts with indented nuclei containing intracytoplasmic lipid vacuoles. The sclerosing variant exhibits prominent collagenous bands separating adipocytic lobules, whereas the inflammatory variant displays a significant lymphoplasmacytic infiltrate. Spindle cell areas may be present; increased cellularity, atypia, or mitotic activity raises concern for dedifferentiation, including low-grade forms. Vascular patterns typically feature thin-walled vessels throughout the adipocytic tissue. Immunohistochemistry reveals strong nuclear expression of MDM2 and CDK4 in atypical cells, serving as diagnostic markers for these cells. Histologic grading defines well-differentiated liposarcomas as grade 1 (low-grade).[15][16] Dedifferentiated Liposarcoma Dedifferentiated liposarcoma subtypes comprises 15% to 20% of liposarcomas and can develop either de novo or progress from well-differentiated liposarcomas. The primary diagnostic feature is an abrupt transition from well-differentiated adipocytic areas to areas without differentiation. The dedifferentiated component often shows high-grade pleomorphic or spindle cell morphology (grade 2 or 3), although low-grade dedifferentiation occurs in about 10% of cases. Necrosis is commonly observed in high-grade dedifferentiation. Mitotic activity is variable and often increased in high-grade dedifferentiated areas. Vascular patterns include both small-caliber vessels and larger, irregular vascular channels in the dedifferentiated areas. Immunohistochemistry reveals MDM2 and CDK4 amplification, similar to that of the well-differentiated component, confirming a shared molecular pathogenesis. Grading is based on the dedifferentiated component, with most classified as grade 2 or 3.[16] Myxoid Liposarcoma

Necrosis is commonly observed in high-grade dedifferentiation. Mitotic activity is variable and often increased in high-grade dedifferentiated areas. Vascular patterns include both small-caliber vessels and larger, irregular vascular channels in the dedifferentiated areas. Immunohistochemistry reveals MDM2 and CDK4 amplification, similar to that of the well-differentiated component, confirming a shared molecular pathogenesis. Grading is based on the dedifferentiated component, with most classified as grade 2 or 3.[16] Myxoid Liposarcoma The myxoid liposarcoma subtype accounts for 30% to 35% of liposarcomas and exhibits distinctive histologic features. At low power, it shows a lobulated architecture with a prominent myxoid matrix composed of hyaluronic acid. Tumor cells appear as uniform, round to oval cells with small nuclei and minimal atypia, arranged in a "chicken-wire" pattern around delicate, arborizing capillaries (plexiform vascular pattern). Lipoblasts at various stages of differentiation are present, ranging from signet-ring cells to multivacuolated forms. The round cell variant demonstrates hypercellularity (>5% round cells) and sheets of primitive round cells lacking myxoid matrix, indicating a higher-grade disease. Mitotic activity is low in conventional myxoid areas (<5 mitoses per 10 high-power fields) but increases significantly in round cell components (>10 mitoses per 10 high-power fields). The characteristic plexiform capillary network provides diagnostic clues. Immunohistochemistry shows S100 positivity in lipoblasts, while MDM2 and CDK4 remain negative. Reverse transcription-polymerase chain reaction (RT-PCR), or FISH, confirms FUS-DDIT3 (95%) or EWSR1-DDIT3 (5%) fusion transcripts. A less than 5% round cell component is considered low-grade; ≥5% defines high-grade myxoid liposarcoma.[16] Pleomorphic Liposarcoma Pleomorphic sarcomas are the rarest subtype, representing 5% to 10% of cases, and are the most aggressive variant. Microscopic examination reveals high-grade pleomorphic sarcoma with scattered pleomorphic lipoblasts characterized by marked nuclear atypia and prominent intracytoplasmic lipid vacuoles indenting hyperchromatic nuclei. The background shows sheets of bizarre, multinucleated giant cells and extensive nuclear pleomorphism.

Pleomorphic sarcomas are the rarest subtype, representing 5% to 10% of cases, and are the most aggressive variant. Microscopic examination reveals high-grade pleomorphic sarcoma with scattered pleomorphic lipoblasts characterized by marked nuclear atypia and prominent intracytoplasmic lipid vacuoles indenting hyperchromatic nuclei. The background shows sheets of bizarre, multinucleated giant cells and extensive nuclear pleomorphism. High mitotic activity (>20 mitoses per 10 high-power fields) and significant necrosis are characteristic features of this condition. Vascular patterns exhibit irregular, dilated vessels. No specific molecular markers have been identified, and diagnosis relies on unequivocal lipoblasts within pleomorphic sarcoma. All cases are classified as grade 3 (high-grade) by definition. Immunohistochemistry shows variable S100 expression but negative MDM2 and CDK4, which helps exclude well-differentiated and dedifferentiated liposarcomas.[16] Grading Grading for nonwell-differentiated subtypes utilizes the French Federation of Cancer Centers Sarcoma Group (FNCLCC) system, which incorporates factors, eg, tumor differentiation (1-3 points), mitotic count (1-3 points), and extent of necrosis (0-2 points) in decision-making. Grade assignment follows a structured point-based system. Grade 1 corresponds to 2 to 3 points, indicating the lowest level within the grading scale. Grade 2 correlates to 4 to 5 points, representing an intermediate level of severity or classification. Grade 3 ranges from 6 to 8 points, reflecting the highest grade in this system (see Table 1). Table Table 1. Liposarcoma Grading .

Clinical Presentations The clinical presentation of liposarcoma can vary significantly depending on the tumor's location, size, and histologic subtype. Most patients are asymptomatic in the early stages of the disease, with tumors often discovered incidentally during imaging for unrelated reasons. Symptoms typically develop when the tumor grows large enough to exert pressure on nearby structures.[17] Extremity liposarcomas most frequently affect the thigh (60% of extremity cases), followed by the buttock, shoulder, and calf. Patients usually present with a painless, slowly enlarging mass. Pain occurs in 30% to 40% of cases due to tumor compression on neurovascular bundles, leading to dull, aching discomfort that may radiate along the corresponding nerve pathways. Neurological symptoms, eg, paresthesias, numbness, or motor weakness, can arise in 15% to 20% of patients due to nerve compression or infiltration. Lower extremity tumors may cause symptoms of venous insufficiency, such as leg swelling, prominent superficial veins, or skin changes due to compression of major veins. Very large tumors (greater than 20 cm) can restrict joint range of motion or cause limb asymmetry. An acute presentation is rare but may occur from tumor hemorrhage or rupture.[17]

Extremity liposarcomas most frequently affect the thigh (60% of extremity cases), followed by the buttock, shoulder, and calf. Patients usually present with a painless, slowly enlarging mass. Pain occurs in 30% to 40% of cases due to tumor compression on neurovascular bundles, leading to dull, aching discomfort that may radiate along the corresponding nerve pathways. Neurological symptoms, eg, paresthesias, numbness, or motor weakness, can arise in 15% to 20% of patients due to nerve compression or infiltration. Lower extremity tumors may cause symptoms of venous insufficiency, such as leg swelling, prominent superficial veins, or skin changes due to compression of major veins. Very large tumors (greater than 20 cm) can restrict joint range of motion or cause limb asymmetry. An acute presentation is rare but may occur from tumor hemorrhage or rupture.[17] Retroperitoneal liposarcomas tend to grow insidiously, often reaching substantial sizes (20-40 cm) and occasionally exceeding 50 cm in diameter before symptoms emerge. Early satiety and vague abdominal fullness are the most common complaints, occurring in 50% to 60% of patients. Abdominal pain is reported in 40% to 50% of cases, typically described as dull, constant discomfort rather than acute pain. Progressive abdominal distention and weight gain caused by a tumor mass can be mistaken for obesity or normal aging. Constitutional symptoms, including fatigue, loss of appetite, and weight loss, occur in 20% to 30% of patients with large or high-grade tumors. Compression of adjacent organs can lead to specific symptoms. Kidney compression may cause flank pain or hematuria, bowel compression can result in constipation or obstipation, duodenal compression can cause nausea, vomiting, or early satiety, and inferior vena cava compression may manifest as lower extremity edema or the formation of superficial venous collaterals. Acute presentations are uncommon but can include tumor rupture with hemorrhage, bowel obstruction, or urinary retention.[18]

Retroperitoneal liposarcomas tend to grow insidiously, often reaching substantial sizes (20-40 cm) and occasionally exceeding 50 cm in diameter before symptoms emerge. Early satiety and vague abdominal fullness are the most common complaints, occurring in 50% to 60% of patients. Abdominal pain is reported in 40% to 50% of cases, typically described as dull, constant discomfort rather than acute pain. Progressive abdominal distention and weight gain caused by a tumor mass can be mistaken for obesity or normal aging. Constitutional symptoms, including fatigue, loss of appetite, and weight loss, occur in 20% to 30% of patients with large or high-grade tumors. Compression of adjacent organs can lead to specific symptoms. Kidney compression may cause flank pain or hematuria, bowel compression can result in constipation or obstipation, duodenal compression can cause nausea, vomiting, or early satiety, and inferior vena cava compression may manifest as lower extremity edema or the formation of superficial venous collaterals. Acute presentations are uncommon but can include tumor rupture with hemorrhage, bowel obstruction, or urinary retention.[18] Truncal liposarcomas located in the chest wall, back, or abdominal wall present as palpable masses with localized swelling. Symptoms are usually minimal unless the tumor presses on underlying structures. Intrathoracic tumors may cause dyspnea, cough, or chest pain when they reach a large size. Head and neck liposarcomas are rare but can present with specific symptoms. Tumors in the oral cavity may lead to difficulties in swallowing or speaking; laryngeal involvement can produce hoarseness or stridor; and neck masses may compress the trachea or esophagus. Physical Examination

Truncal liposarcomas located in the chest wall, back, or abdominal wall present as palpable masses with localized swelling. Symptoms are usually minimal unless the tumor presses on underlying structures. Intrathoracic tumors may cause dyspnea, cough, or chest pain when they reach a large size. Head and neck liposarcomas are rare but can present with specific symptoms. Tumors in the oral cavity may lead to difficulties in swallowing or speaking; laryngeal involvement can produce hoarseness or stridor; and neck masses may compress the trachea or esophagus. Physical Examination Physical examination findings depend on the tumor's location and size. Extremity tumors typically present as firm to soft masses with well-defined or indistinct borders. At diagnosis, tumor sizes usually range from 5 to 30 cm (with a median size of 10-15 cm). Deep-seated tumors feel firm and fixed to underlying tissues, while superficial tumors tend to be more movable. The skin overlying the tumor usually appears normal without signs of ulceration, erythema, or warmth unless the tumor has grown to a massive size, causing skin thinning. Palpation generally elicits minimal tenderness unless a high-grade tumor with necrosis is present. A neurovascular examination might reveal motor weakness, sensory deficits, or diminished pulses due to compression. Measuring and comparing the affected limb with the contralateral limb can document limb asymmetry.[17] Retroperitoneal tumors often present with abdominal distention and fullness in the flank or upper quadrant. Deep palpation may reveal a firm, non-tender mass with a smooth or nodular contour; smaller tumors (less than 15 cm) may not be palpable. Large tumors can cause asymmetric abdominal distension, and bowel sounds are usually present unless obstruction has occurred. Signs of lower extremity edema or the presence of superficial venous collaterals may indicate venous compression.

Retroperitoneal tumors often present with abdominal distention and fullness in the flank or upper quadrant. Deep palpation may reveal a firm, non-tender mass with a smooth or nodular contour; smaller tumors (less than 15 cm) may not be palpable. Large tumors can cause asymmetric abdominal distension, and bowel sounds are usually present unless obstruction has occurred. Signs of lower extremity edema or the presence of superficial venous collaterals may indicate venous compression. High-grade tumors occasionally present with symptoms of cachexia, palpable lymphadenopathy (rare, seen in less than 5% of cases), or signs of metastatic disease. Pulmonary metastases can result in tachypnea or decreased breath sounds, while bone metastases (especially with the myxoid subtype) may cause localized bone tenderness. Red flag symptoms that require urgent evaluation include a rapidly enlarging mass (greater than 1 cm per month), severe or progressively worsening pain, neurologic deficits, constitutional symptoms (fever, night sweats, weight loss), or acute abdominal symptoms suggesting hemorrhage or organ compression.[17]

A comprehensive evaluation of suspected liposarcoma requires a systematic approach that includes imaging, tissue diagnosis, and staging to determine the treatment strategy and prognosis. Laboratory Studies Complete blood count with differential, comprehensive metabolic panel, and lactate dehydrogenase (LDH) should be obtained in all patients. Necrotic tumors can cause leukocytosis, and rapidly proliferating tumors can elevate LDH levels. Renal function should be assessed as nephrectomy may be indicated in treating retroperitoneal tumors. Assessment is critical for retroperitoneal tumors, as kidney involvement or compression may necessitate nephrectomy during resection. Liver function tests identify hepatic dysfunction from tumor compression or metastatic disease. Imaging Studies An MRI with contrast is considered the optimal diagnostic test for most sarcomas, especially those located in the extremities, those arising from the soft tissues of the abdomen and trunk, and those in the head and neck. The MRI signal intensity of liposarcomas is variable and heterogeneous, depending on the tumor's components and histological patterns. Myxoid liposarcomas appear as areas of low signal intensity on T1-weighted images and high signal intensity on T2-weighted images. Postcontrast images of myxoid liposarcoma reveal enhanced solid tissues and thickened septa. Well-differentiated liposarcomas exhibit high signal intensity on T1-weighted images, intermediate signal intensity on T2-weighted images, and signal dropout on fat-suppressed MRI images. Postcontrast images show enhanced, delicate septa and solid tissues.[19] Round-cell and pleomorphic liposarcomas exhibit soft-tissue tumor signal intensity without distinct fat signals. Dedifferentiated liposarcomas show small fatty components with a clear boundary between fat and non-fat solid tissue on MRI images.[19] Computed tomography

Well-differentiated liposarcomas exhibit high signal intensity on T1-weighted images, intermediate signal intensity on T2-weighted images, and signal dropout on fat-suppressed MRI images. Postcontrast images show enhanced, delicate septa and solid tissues.[19] Round-cell and pleomorphic liposarcomas exhibit soft-tissue tumor signal intensity without distinct fat signals. Dedifferentiated liposarcomas show small fatty components with a clear boundary between fat and non-fat solid tissue on MRI images.[19] Computed tomography CT with intravenous contrast is the imaging modality of choice for retroperitoneal, intra-abdominal, and intrathoracic liposarcomas, providing excellent visualization of these anatomic regions and assessment of organ involvement. Fat attenuation (ranging from -50 to -150 Hounsfield units) in well-differentiated components, with thickened septa and soft tissue nodules, typically indicates aggressive disease. Dedifferentiated areas show solid soft tissue attenuation with heterogeneous enhancement. CT defines involvement of the kidneys, pancreas, bowel, major vessels, and bony structures. Multiplanar reconstructions assist surgical planning. For extremity tumors where MRI is contraindicated or unavailable, CT provides adequate characterization, though with inferior soft tissue resolution. Chest CT is recommended for staging, particularly in intermediate- and high-grade tumors. The lung is the most common site of metastasis for most soft tissue sarcomas.[20] Positron emission tomography Positron emission tomography (PET)/CT with 18F-fluorodeoxyglucose (FDG) T is not routinely performed but offers value in specific scenarios. High-grade dedifferentiated, round cell, and pleomorphic liposarcomas demonstrate avid FDG uptake (SUVmax >3-4), while well-differentiated and low-grade myxoid tumors show minimal uptake (SUVmax <2-3). PET/CT aids in distinguishing between well-differentiated and dedifferentiated liposarcoma in large, heterogeneous tumors, with focal areas of intense uptake guiding biopsy to the highest-grade regions. PET/CT assists in detecting occult metastases in high-grade tumors and evaluating treatment response to neoadjuvant chemotherapy. Whole-body PET/CT may identify unexpected sites of myxoid liposarcoma metastases, including bone, soft tissues, and retroperitoneum.[21] Tissue Diagnosis Image-guided core needle biopsy

Positron emission tomography (PET)/CT with 18F-fluorodeoxyglucose (FDG) T is not routinely performed but offers value in specific scenarios. High-grade dedifferentiated, round cell, and pleomorphic liposarcomas demonstrate avid FDG uptake (SUVmax >3-4), while well-differentiated and low-grade myxoid tumors show minimal uptake (SUVmax <2-3). PET/CT aids in distinguishing between well-differentiated and dedifferentiated liposarcoma in large, heterogeneous tumors, with focal areas of intense uptake guiding biopsy to the highest-grade regions. PET/CT assists in detecting occult metastases in high-grade tumors and evaluating treatment response to neoadjuvant chemotherapy. Whole-body PET/CT may identify unexpected sites of myxoid liposarcoma metastases, including bone, soft tissues, and retroperitoneum.[21] Tissue Diagnosis Image-guided core needle biopsy Core needle biopsy under CT or ultrasound guidance constitutes the diagnostic standard for suspected liposarcoma. This approach provides adequate tissue for histologic examination, immunohistochemistry, and molecular testing while minimizing complications. The biopsy tract should be planned along the anticipated surgical incision line to facilitate en bloc excision of the tract during definitive surgery. For heterogeneous tumors, multiple cores (a minimum of 4-6 samples) from different regions, particularly areas showing solid enhancement or high metabolic activity on PET/CT, are recommended to optimize diagnostic yield. Core needle biopsies should be obtained from viable tumor regions, avoiding necrotic or cystic areas. Image guidance ensures accurate targeting of deep-seated lesions. Complications of this study, including hemorrhage, infection, and tumor seeding, occur in fewer than 1% of cases.[22][23] Tumor seeding along the biopsy tract remains exceedingly rare (<0.01%) and does not impact survival when the tract is excised during definitive resection.[22][24][25] Fine needle aspiration (FNA) is generally inadequate for diagnosing liposarcoma, as cytology alone cannot reliably distinguish between malignant and benign adipocytic lesions, determine the histologic subtype, or provide tissue for molecular studies. FNA should be avoided except when lymphoma remains in the differential diagnosis and flow cytometry is required. Incisional or excisional biopsy

Fine needle aspiration (FNA) is generally inadequate for diagnosing liposarcoma, as cytology alone cannot reliably distinguish between malignant and benign adipocytic lesions, determine the histologic subtype, or provide tissue for molecular studies. FNA should be avoided except when lymphoma remains in the differential diagnosis and flow cytometry is required. Incisional or excisional biopsy Open surgical biopsy, whether incisional or excisional, is generally discouraged for suspected soft-tissue sarcomas, except when the core biopsy is nondiagnostic. This approach risks tumor spillage, contamination of tissue planes, hematoma formation, and distortion of anatomic boundaries crucial for subsequent definitive resection. Excisional biopsy of suspected benign lipomas performed without preoperative imaging or oncologic surgical technique frequently yields surprise pathology of liposarcoma, resulting in compromised margins, contaminated surgical fields, and increased local recurrence risk. If a surgical biopsy becomes necessary due to inadequate core biopsy specimens, an incisional biopsy should be performed through a limited longitudinal incision along the anticipated definitive resection plane, obtaining representative tissue while minimizing disruption of tissue planes.[26][27][28] Molecular and Genetic Testing Molecular diagnostics provide valuable diagnostic confirmation and prognostic information. MDM2 gene amplification, detected by fluorescence in situ hybridization (FISH), confirms the diagnosis of well-differentiated or dedifferentiated liposarcoma in equivocal cases, particularly when distinguishing it from benign lipomatous tumors. Next-generation sequencing panels identify characteristic fusion genes in myxoid liposarcoma (FUS-DDIT3, EWSR1-DDIT3), which are pathognomonic for this subtype. Molecular testing aids in distinguishing liposarcoma subtypes from morphologic mimics, including pleomorphic lipoma, spindle cell lipoma, and other adipocytic lesions. Comprehensive genomic profiling may identify actionable mutations in recurrent or metastatic disease, informing enrollment in clinical trials of targeted therapies. Staging Evaluation

Molecular diagnostics provide valuable diagnostic confirmation and prognostic information. MDM2 gene amplification, detected by fluorescence in situ hybridization (FISH), confirms the diagnosis of well-differentiated or dedifferentiated liposarcoma in equivocal cases, particularly when distinguishing it from benign lipomatous tumors. Next-generation sequencing panels identify characteristic fusion genes in myxoid liposarcoma (FUS-DDIT3, EWSR1-DDIT3), which are pathognomonic for this subtype. Molecular testing aids in distinguishing liposarcoma subtypes from morphologic mimics, including pleomorphic lipoma, spindle cell lipoma, and other adipocytic lesions. Comprehensive genomic profiling may identify actionable mutations in recurrent or metastatic disease, informing enrollment in clinical trials of targeted therapies. Staging Evaluation Complete staging evaluation includes imaging of the primary tumor (MRI or CT), chest CT, and abdominal/pelvic CT for retroperitoneal tumors. Whole-body imaging (PET/CT or whole-body MRI) should be considered for myxoid liposarcoma and high-grade tumors. Targeted imaging (MRI or PET) may be used if bone metastases are suspected. Lymph node assessment through physical examination and imaging is performed, though nodal metastases occur in fewer than 5% of cases.

Management of liposarcoma requires a collaborative, interprofessional approach involving surgical, medical, and radiation oncology specialists. Surgical resection serves as the primary treatment, aiming for complete tumor removal with negative margins. Complex anatomical locations often pose technical challenges, making margin-negative resection difficult in some cases. Retroperitoneal sarcomas, in particular, demand specialized consideration, and a separate StatPearls article provides an in-depth discussion of their evaluation and management strategies.

The differential diagnosis of liposarcoma includes the following benign adipocytic lesions and other soft tissue tumors that may demonstrate similar clinical or radiologic features: Lipoma: Benign adipocytic tumor composed entirely of mature adipocytes without atypia, nuclear enlargement, or MDM2 amplification Lipoblastoma: Benign adipocytic tumor occurring predominantly in infants and young children (typically younger than 5), composed of immature adipocytes and characterized by PLAG1 rearrangements Hibernoma: Benign tumor of brown fat demonstrating multivacuolated cells with granular cytoplasm and a central nucleus; associated with rearrangements involving chromosome 11q (often 11q13–21) Spindle cell/pleomorphic lipoma: Benign lesion with spindle cells, ropy collagen bundles, and mature adipocytes; characterized by RB1 and chromosome 13q deletions Myxofibrosarcoma: High-grade myxoid sarcoma lacking lipoblasts; shows infiltrative growth and curvilinear vessels; lacks pathognomonic fusion genes but demonstrates complex cytogenetic abnormalities Pleomorphic rhabdomyosarcoma: High-grade sarcoma with pleomorphic cells and occasional rhabdomyoblasts showing cross-striations; desmin and myogenin positive Undifferentiated pleomorphic sarcoma: High-grade sarcoma without a specific line of differentiation; lacks lipoblasts and has no MDM2 amplification Malignant peripheral nerve sheath tumor: High-grade sarcoma associated with neurofibromatosis type 1; S100 focally positive, lacks MDM2 amplification Leiomyosarcoma: Malignant smooth muscle tumor with fascicular architecture, cigar-shaped nuclei; SMA and desmin positive Myxoma: Benign myxoid lesion composed of bland stellate cells in abundant myxoid matrix; lacks lipoblasts and plexiform vasculature Hematoma/seroma: May mimic soft tissue mass on examination; ultrasound or MRI demonstrates fluid collection without solid components Abscess: Presents with pain, fever, and inflammatory markers; imaging shows rim-enhancing fluid collection with surrounding edema

Complete surgical resection with negative margins is the definitive treatment for localized liposarcoma. Complete macroscopic resection with negative or close microscopic margins is the primary determinant of disease-specific survival. Given the complexity and rarity of these tumors, patients should be referred to high-volume sarcoma centers with interprofessional expertise for optimal outcomes.[29] Extremity Liposarcoma The surgical approach for extremity tumors is wide local excision, achieving negative margins while preserving limb function. The tumor, surrounding pseudocapsule, and adjacent cuff of normal tissue should be resected en bloc. Well-differentiated liposarcomas often respect fascial planes, whereas dedifferentiated and pleomorphic subtypes commonly demonstrate infiltrative growth. Excision should include the investing fascia to maximize margin adequacy. Margins of 1 to 2 cm in peripheral directions are desirable when anatomically feasible, though smaller margins are acceptable when abutting critical neurovascular structures. Sacrificing major neurovascular bundles or bone is rarely necessary for low-grade tumors, but may be required for high-grade tumors with direct invasion. Vascular reconstruction using autologous vein grafts or synthetic conduits restores arterial perfusion when major vessel resection is necessary. Nerve grafting or nerve transfer procedures may be performed for the reconstruction of motor nerves. Bone resection with prosthetic reconstruction or allograft is occasionally required for tumors invading the femur or other long bones. Soft tissue defects are closed primarily when possible; large defects require reconstruction with local or free flaps, particularly when preoperative radiation has been administered. Prior biopsy tracts must be excised en bloc with the specimen.[30][17] Retroperitoneal Liposarcoma En bloc resection of the tumor, including directly involved organs, is the standard approach for treatment. Please see StatPearls' companion resource, "Retroperitoneal Liposarcoma," for further information.[29] Truncal Liposarcoma

Vascular reconstruction using autologous vein grafts or synthetic conduits restores arterial perfusion when major vessel resection is necessary. Nerve grafting or nerve transfer procedures may be performed for the reconstruction of motor nerves. Bone resection with prosthetic reconstruction or allograft is occasionally required for tumors invading the femur or other long bones. Soft tissue defects are closed primarily when possible; large defects require reconstruction with local or free flaps, particularly when preoperative radiation has been administered. Prior biopsy tracts must be excised en bloc with the specimen.[30][17] Retroperitoneal Liposarcoma En bloc resection of the tumor, including directly involved organs, is the standard approach for treatment. Please see StatPearls' companion resource, "Retroperitoneal Liposarcoma," for further information.[29] Truncal Liposarcoma Chest wall and abdominal wall tumors require wide local excision, including overlying skin, underlying ribs or muscle, and peritoneum or pleura when involved. Significant defects are reconstructed with mesh (polypropylene or biologic) and soft tissue coverage using muscle flaps (latissimus dorsi, rectus abdominis) or free flaps. Intrathoracic Liposarcoma Mediastinal tumors typically require median sternotomy or anterolateral thoracotomy. Resection may necessitate pericardectomy, lung resection, or great vessel reconstruction. Cardiothoracic surgical expertise is essential. Pleural-based tumors are approached through thoracotomy with extrapleural dissection or pleurectomy. Pelvic Liposarcoma Pelvic tumors often require multivisceral resection, including partial cystectomy, proctectomy, or sacrectomy. Urologic and colorectal surgical expertise is frequently required. Extensive pelvic resections may necessitate permanent urinary or fecal diversion. Margin Status

Mediastinal tumors typically require median sternotomy or anterolateral thoracotomy. Resection may necessitate pericardectomy, lung resection, or great vessel reconstruction. Cardiothoracic surgical expertise is essential. Pleural-based tumors are approached through thoracotomy with extrapleural dissection or pleurectomy. Pelvic Liposarcoma Pelvic tumors often require multivisceral resection, including partial cystectomy, proctectomy, or sacrectomy. Urologic and colorectal surgical expertise is frequently required. Extensive pelvic resections may necessitate permanent urinary or fecal diversion. Margin Status The primary surgical goal is R0 resection (ie, negative microscopic margins). However, an R1 resection (microscopically positive margins) is often acceptable in extremity tumors treated with adjuvant radiation and may achieve local control approaching R0; however, in retroperitoneal disease, R1 margins are associated with worse outcomes. R2 resection (gross residual disease) is associated with significantly worse survival and should be avoided outside palliative settings. For extremity tumors, achieving negative margins is more feasible and should be prioritized.[30][17] Recurrent Disease Management Surgical re-resection for locally recurrent disease improves survival when technically feasible and should be pursued in appropriate candidates. Favorable prognostic factors for re-resection include a long disease-free interval (12-24 months or more), prior R0 resection, low-to-intermediate-grade histology, unifocal recurrence, and good performance status. Multiple recurrences, rapid progression exceeding 1 cm per month, high-grade dedifferentiated or pleomorphic histology, and multifocal disease portend worse outcomes following re-resection. Palliative surgical debulking may be offered for symptom relief, including obstruction, bleeding, or pain, in patients with unresectable local recurrence or limited metastatic disease.[30][17][29]

Radiation therapy serves as an essential adjunct to surgical resection for improving local control, particularly in high-grade extremity liposarcomas, large tumors (>5 cm), and tumors with close or positive margins.[29] Preoperative (Neoadjuvant) Radiation Preoperative radiation therapy is generally preferred over postoperative approaches for extremity and truncal sarcomas. Advantages include a lower total radiation dose (50 Gy preoperatively versus 60-66 Gy postoperatively), a more precisely defined target volume, a smaller radiation field, reduced late fibrosis and joint stiffness, and potential tumor downstaging, facilitating margin-negative resection. The primary disadvantage involves increased wound complication rates (30%-35% versus 15%-20% for postoperative radiation), particularly for lower extremity and groin tumors. Standard preoperative dosing delivers 50 to 50.4 Gy in 25 to 28 fractions over 5 to 5.5 weeks. Surgery is typically scheduled 4 to 6 weeks following radiation completion to allow acute radiation effects to resolve while maximizing tumor response. Myxoid liposarcoma demonstrates marked radiosensitivity, often showing substantial tumor shrinkage that may facilitate less extensive surgical resection. Well-differentiated liposarcoma is generally not treated with radiation therapy due to the low risk of local recurrence following complete resection, but radiation may be considered for recurrent, large, or margin-positive tumors. Dedifferentiated, pleomorphic, and round cell variants warrant consideration for radiation therapy based on size and grade.[31] Postoperative (Adjuvant) Radiation Adjuvant radiation therapy is administered when preoperative radiation was not given, and the final pathology reveals high-risk features, including high-grade tumors, large size (>5 cm), or close/positive margins. Standard dosing delivers 60 to 64 Gy in 30 to 32 fractions to the tumor bed with margin. Boost doses of 66 Gy may be administered to regions of positive margins or high-risk areas. Adjuvant radiation reduces the risk of local recurrence but does not improve overall survival. The decision to administer adjuvant radiation involves balancing local control benefit against increased late toxicity compared to preoperative approaches.[31] Retroperitoneal Liposarcoma Radiation

Adjuvant radiation therapy is administered when preoperative radiation was not given, and the final pathology reveals high-risk features, including high-grade tumors, large size (>5 cm), or close/positive margins. Standard dosing delivers 60 to 64 Gy in 30 to 32 fractions to the tumor bed with margin. Boost doses of 66 Gy may be administered to regions of positive margins or high-risk areas. Adjuvant radiation reduces the risk of local recurrence but does not improve overall survival. The decision to administer adjuvant radiation involves balancing local control benefit against increased late toxicity compared to preoperative approaches.[31] Retroperitoneal Liposarcoma Radiation The use of radiation therapy for retroperitoneal liposarcoma remains controversial, with varying practice patterns. Preoperative radiation (45-50.4 Gy) is preferred when administered, as it allows smaller treatment volumes and lower doses to adjacent normal organs (kidneys, liver, bowel). Postoperative radiation is technically challenging due to large treatment volumes and dose-limiting bowel within the resection bed. Studies have shown modest improvements in local control with preoperative radiation, but no clear survival benefit. Radiation is typically reserved for high-grade tumors, anticipated close margins, or recurrent disease. Intraoperative radiation therapy (IORT), which delivers a single 10 to 15 Gy boost to the tumor bed during surgery, may improve local control in specialized centers.[32] Radiation Techniques Modern radiation delivery employs intensity-modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) to optimize target coverage while minimizing dose to adjacent normal tissues. Treatment planning typically includes CT simulation, with or without MRI fusion, for target delineation. Organs at risk (bone, joints, neurovascular structures, kidneys, and bowel) are contoured, and dose constraints are applied. Respiratory gating or breath-hold techniques reduce target motion for trunk and abdominal tumors. Proton beam therapy may offer dosimetric advantages for pediatric patients or tumors located in proximity to critical structures, but it is not routinely required.[29] Palliative Radiation

Modern radiation delivery employs intensity-modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) to optimize target coverage while minimizing dose to adjacent normal tissues. Treatment planning typically includes CT simulation, with or without MRI fusion, for target delineation. Organs at risk (bone, joints, neurovascular structures, kidneys, and bowel) are contoured, and dose constraints are applied. Respiratory gating or breath-hold techniques reduce target motion for trunk and abdominal tumors. Proton beam therapy may offer dosimetric advantages for pediatric patients or tumors located in proximity to critical structures, but it is not routinely required.[29] Palliative Radiation Palliative radiation therapy effectively alleviates symptoms in patients with unresectable primary tumors or metastatic disease. Short-course regimens (20-30 Gy in 5-10 fractions or 8 Gy in 1 fraction) palliate pain, bleeding, or mass effect in 60% to 70% of patients with acceptable toxicity. Longer-course palliative radiation (40-50 Gy) may be employed for potentially resectable tumors or when prolonged local control is desired.[29]

Systemic therapy depends on the histologic subtype, grade, stage, and clinical scenario. Well-differentiated liposarcoma is largely chemoresistant, and systemic treatment is rarely used. Dedifferentiated and pleomorphic liposarcomas show moderate chemosensitivity. Myxoid liposarcoma is more chemosensitive than other subtypes, particularly in tumors with higher round-cell components, with reported response rates of approximately 30% to 40% with anthracycline-based regimens.[29][33] First-Line Therapy for Advanced Disease Doxorubicin is the first-line agent for advanced, metastatic, or unresectable liposarcoma, often combined with ifosfamide in medically fit patients. The standard regimen is doxorubicin 75 mg/m² on day 1, with or without ifosfamide 10 g/m² as a continuous infusion over 3 days, with mesna uroprotection, repeated every 21 days. Response rates are 20% to 30% for single-agent doxorubicin and 30% to 40% for combination therapy. Myxoid liposarcoma achieves higher response rates (40%-50%) with doxorubicin plus ifosfamide or trabectedin, though high-grade round cell components are less responsive.[34] Doxorubicin cardiotoxicity limits cumulative dosing to 450-550 mg/m²; cardiac monitoring with echocardiography or MUGA scan is required at baseline and during treatment. For older adult patients or those with cardiac comorbidities, single-agent doxorubicin or liposomal formulations are preferred to reduce cardiac toxicity.[29][35] Second-Line Therapy

Myxoid liposarcoma achieves higher response rates (40%-50%) with doxorubicin plus ifosfamide or trabectedin, though high-grade round cell components are less responsive.[34] Doxorubicin cardiotoxicity limits cumulative dosing to 450-550 mg/m²; cardiac monitoring with echocardiography or MUGA scan is required at baseline and during treatment. For older adult patients or those with cardiac comorbidities, single-agent doxorubicin or liposomal formulations are preferred to reduce cardiac toxicity.[29][35] Second-Line Therapy Two FDA-approved agents have shown efficacy after anthracycline failure. Trabectedin, a marine-derived alkaloid that interferes with DNA repair and transcription, is administered at a dose of 1.5 mg/m² as a 24-hour continuous infusion every 21 days. Trabectedin targets the FUS-DDIT3 fusion protein in myxoid liposarcoma, achieving disease control rates of 50% to 60% with a median progression-free survival of 4 to 5 months. Myxoid liposarcoma responds better than other subtypes. Main toxicities include myelosuppression, hepatotoxicity (reduced by dexamethasone premedication), and fatigue. Eribulin, a microtubule inhibitor, is administered intravenously at a dose of 1.4 mg/m² on days 1 and 8 of a 21-day cycle. The Phase III Cortes trial demonstrated improved overall survival (13.5 months versus 11.5 months for dacarbazine; HR, 0.77; p = 0.017), with a particularly notable benefit in liposarcoma. Toxicities include neutropenia, peripheral neuropathy, and fatigue.[29] Alternative second-line options include gemcitabine 900 mg/m² on days 1 and 8 with docetaxel 75 mg/m² on day 8 every 21 days, yielding response rates of 15% to 20% and a median progression-free survival of 5 to 6 months in patients with dedifferentiated or pleomorphic subtypes. Pazopanib has limited activity in liposarcoma and is generally not recommended outside clinical trials or exceptional circumstances.[29] Targeted Therapies Under Investigation

Alternative second-line options include gemcitabine 900 mg/m² on days 1 and 8 with docetaxel 75 mg/m² on day 8 every 21 days, yielding response rates of 15% to 20% and a median progression-free survival of 5 to 6 months in patients with dedifferentiated or pleomorphic subtypes. Pazopanib has limited activity in liposarcoma and is generally not recommended outside clinical trials or exceptional circumstances.[29] Targeted Therapies Under Investigation MDM2 and CDK4 amplification in well-differentiated and dedifferentiated liposarcoma provide rational therapeutic targets. Palbociclib, a selective CDK4/6 inhibitor, has shown disease stabilization in 60% to 70% of patients, with a median progression-free survival of 4 months in early-phase trials, though objective response rates remain low (<10%). Combination approaches with PI3K or mTOR inhibitors are being evaluated. MDM2 antagonists, including idasanutlin, milademetan, and brigimadlin, are in phase 1 to 2 trials for MDM2-amplified tumors, showing disease stabilization in 40% to 60% of patients with acceptable toxicity. These agents are being tested as monotherapy and combined with chemotherapy. Neither palbociclib nor MDM2 antagonists are currently FDA-approved for liposarcoma, though both are being evaluated in clinical trials.[29] Perioperative Chemotherapy The role of neoadjuvant and adjuvant chemotherapy is controversial, with limited supporting evidence. Neoadjuvant chemotherapy may be considered for borderline resectable high-grade extremity tumors (>10 cm) to facilitate margin-negative resection, using anthracycline-based regimens for 2 to 3 cycles followed by restaging and surgery. Adjuvant chemotherapy after complete resection is generally not recommended outside of clinical trials, as the ISG-STS 1001 trial and other prospective, randomized studies have failed to show a significant survival benefit. Adjuvant therapy may be considered on an individual basis for young patients with high-grade, large (>10 cm) extremity tumors, acknowledging limited evidence. Myxoid liposarcoma with high-grade round cell component (>5%) may warrant adjuvant chemotherapy consideration given chemosensitivity and metastatic risk.[29] Immunotherapy

The role of neoadjuvant and adjuvant chemotherapy is controversial, with limited supporting evidence. Neoadjuvant chemotherapy may be considered for borderline resectable high-grade extremity tumors (>10 cm) to facilitate margin-negative resection, using anthracycline-based regimens for 2 to 3 cycles followed by restaging and surgery. Adjuvant chemotherapy after complete resection is generally not recommended outside of clinical trials, as the ISG-STS 1001 trial and other prospective, randomized studies have failed to show a significant survival benefit. Adjuvant therapy may be considered on an individual basis for young patients with high-grade, large (>10 cm) extremity tumors, acknowledging limited evidence. Myxoid liposarcoma with high-grade round cell component (>5%) may warrant adjuvant chemotherapy consideration given chemosensitivity and metastatic risk.[29] Immunotherapy Immune checkpoint inhibitors, including pembrolizumab and nivolumab, have limited activity in liposarcoma, with objective response rates of 5% to 10% in unselected patients. Pleomorphic liposarcoma, which has a higher mutational burden, may be more responsive, though confirmatory data are needed. Combination approaches with chemotherapy, targeted agents, or radiation are under investigation. Immunotherapy is not currently recommended as standard therapy outside clinical trials.[29] Clinical Trial Enrollment Enrollment in clinical trials is strongly encouraged for patients with advanced, unresectable, or metastatic liposarcoma. Novel agents under investigation include MDM2 inhibitors for MDM2-amplified tumors, immune checkpoint combinations, NTRK inhibitors for rare cases with NTRK gene fusions, epigenetic modulators, and metabolic inhibitors. Comprehensive genomic profiling using next-generation sequencing may identify actionable alterations for biomarker-selected studies. Tumor mutational burden and microsatellite instability testing can help identify candidates for immunotherapy.[29]

The eighth edition of the tumor, node, metastasis (TNM) system, established by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC), is used to stage retroperitoneal liposarcomas. This system includes distinct prognostic stage groupings that emphasize the importance of tumor grade, as noted in the table below, which is included in the AJCC/UICC staging system (see Tables 2 and 3). The latest guidelines classify tumors into the following 3 grades based on the degree of differentiation, mitotic activity, and necrosis: Grade 1: Low-grade tumors Grade 2: Intermediate to high-grade tumors Grade 3: High-grade tumors [36] Table Table 2. The Eighth Edition American Joint Committee on Cancer Cancer Staging for Retroperitoneal Sarcoma. Table 3. Prognostic Groups Table Reference for Table 3 [36]

Prognosis varies substantially based on histologic subtype, tumor grade, anatomic location, and surgical margin status, with 5-year overall survival ranging from 30% to 95% across different clinical scenarios. Histologic Subtype Prognosis Well-differentiated liposarcoma Well-differentiated liposarcoma has an excellent prognosis with 5-year disease-specific survival exceeding 95% when completely resected from extremity or trunk locations. These tumors carry a 10% to 30% local recurrence risk in extremity sites and 40% to 60% recurrence risk in retroperitoneal locations due to challenges in achieving negative margins. These tumors have minimal intrinsic metastatic potential, but may metastasize following dedifferentiation, particularly in retroperitoneal disease. Dedifferentiation occurs in approximately 10% to 15% of retroperitoneal tumors and in less than 5% of extremity tumors during long-term follow-up, significantly altering prognosis.[3][37] Dedifferentiated liposarcoma Dedifferentiated liposarcoma exhibits an intermediate prognosis, with a 5-year overall survival rate of 50% to 70% and a disease-specific survival rate of 60% to 75%. Extremity dedifferentiated tumors show improved outcomes compared with retroperitoneal disease, with a reported 5-year survival of approximately 55% to 70% due to more frequent margin-negative resections. Metastatic disease develops in 15% to 30% of patients, most commonly to the lungs but also to the liver, bone, and intra-abdominal sites, particularly in retroperitoneal disease. Local recurrence rates reach 40% to 50% for retroperitoneal disease and 20% to 30% for extremity tumors. Low-grade dedifferentiation (grade 1-2 dedifferentiated component) confers a better prognosis than high-grade dedifferentiation. Complete surgical resection with negative margins is the most critical prognostic factor; R0 resection is associated with the best outcomes, while R1 resections show intermediate survival, and R2 resections are associated with a markedly inferior prognosis. Myxoid liposarcoma

Local recurrence rates reach 40% to 50% for retroperitoneal disease and 20% to 30% for extremity tumors. Low-grade dedifferentiation (grade 1-2 dedifferentiated component) confers a better prognosis than high-grade dedifferentiation. Complete surgical resection with negative margins is the most critical prognostic factor; R0 resection is associated with the best outcomes, while R1 resections show intermediate survival, and R2 resections are associated with a markedly inferior prognosis. Myxoid liposarcoma Myxoid liposarcoma has a favorable-to-intermediate prognosis, depending on the percentage of round cells. Pure myxoid tumors (<5% round cells) show 70% to 85% 5-year overall survival with 10% to 15% metastatic risk. Tumors containing 5% to 25% round cells have 60% to 70% 5-year survival and 30% to 40% metastatic potential. High-grade round cell liposarcoma (>25% round cells) exhibits aggressive behavior, with a 5-year survival rate of 40% to 50% and a metastatic rate of 50% to 60%. The unique metastatic pattern involves extrapulmonary soft tissue sites (30-40%), bone (25-35%), and retroperitoneum (15-20%) in addition to conventional lung metastases (40-50%), supporting the use of chest imaging and consideration of site-directed surveillance of extrapulmonary sites. Myxoid liposarcoma shows notable chemosensitivity and radiosensitivity, potentially improving outcomes with multimodal therapy.[38] Pleomorphic liposarcoma Pleomorphic liposarcoma is the most aggressive subtype with the poorest prognosis. The 5-year overall and disease-specific survival rates are approximately 30% to 50%. Metastatic disease develops in 30% to 50% of patients, predominantly to the lungs, typically within the first 2 years following diagnosis. Local recurrence rates reach 30% to 40% despite aggressive surgical resection and adjuvant radiation. Adverse prognostic factors include tumor size exceeding 10 cm, high mitotic rate (>20 mitoses per 10 high-power fields), extensive necrosis (>50%), and truncal or retroperitoneal location.[39] Additional Prognostic Factors

Pleomorphic liposarcoma is the most aggressive subtype with the poorest prognosis. The 5-year overall and disease-specific survival rates are approximately 30% to 50%. Metastatic disease develops in 30% to 50% of patients, predominantly to the lungs, typically within the first 2 years following diagnosis. Local recurrence rates reach 30% to 40% despite aggressive surgical resection and adjuvant radiation. Adverse prognostic factors include tumor size exceeding 10 cm, high mitotic rate (>20 mitoses per 10 high-power fields), extensive necrosis (>50%), and truncal or retroperitoneal location.[39] Additional Prognostic Factors Anatomic location has a significant impact on prognosis, independent of histologic subtype. Extremity tumors have superior outcomes compared to retroperitoneal tumors across all subtypes, with 5-year overall survival of 70% to 80% versus 50% to 60%, respectively. This survival advantage reflects the greater feasibility of margin-negative resection, lower local recurrence rates, and earlier detection of extremity tumors. Retroperitoneal location confers a 2- to 3-fold increased risk of local recurrence and a 1.5- to 2-fold increased risk of mortality. Truncal tumors show an intermediate prognosis between extremity and retroperitoneal sites. Additional adverse prognostic factors include large tumor size (>10 cm), positive or close surgical margins (<1 mm), high tumor grade (grade 2-3), advanced patient age (>60 years), and recurrent disease. Margin status is a critical modifiable factor, with R0 resection improving survival by 20% to 30% compared with R1 resection and by 40% to 50% compared with R2 resection across all subtypes. Tumor size correlates with recurrence risk and mortality. Very large tumors are associated with increased recurrence and mortality risk, although the magnitude varies by subtype and location.

A broad range of complications is associated with liposarcomas, which vary according to tumor location, disease extent, and histologic subtype. A detailed discussion of these complications falls outside the scope of this course.

Currently, no evidence-based preventive strategies exist to reduce liposarcoma incidence, as the vast majority of cases occur sporadically without identifiable modifiable risk factors or genetic predisposition. Patients should be counseled that liposarcoma development is not attributable to lifestyle factors, obesity, dietary habits, or prior trauma. For individuals with occupational exposure to herbicides, dioxins, or other potential carcinogens, standard workplace safety measures, including protective equipment and exposure monitoring, should be maintained, though the absolute risk increase for sarcoma development is modest. Patients with prior therapeutic radiation exposure should be educated regarding the small but measurable long-term risk of secondary sarcoma development, with latency periods typically ranging from 8 to 20 years postradiation. These individuals should undergo periodic clinical examinations of irradiated fields during routine follow-up visits, with any new or persistent mass prompting an imaging evaluation. Individuals with hereditary cancer predisposition syndromes, particularly Li-Fraumeni syndrome, require genetic counseling and discussion of enhanced surveillance strategies, including annual whole-body MRI screening. However, specific surveillance protocols for liposarcoma are undefined. Family members of patients with Li-Fraumeni syndrome should be offered genetic testing to assess inherited cancer risk.

Patients with prior therapeutic radiation exposure should be educated regarding the small but measurable long-term risk of secondary sarcoma development, with latency periods typically ranging from 8 to 20 years postradiation. These individuals should undergo periodic clinical examinations of irradiated fields during routine follow-up visits, with any new or persistent mass prompting an imaging evaluation. Individuals with hereditary cancer predisposition syndromes, particularly Li-Fraumeni syndrome, require genetic counseling and discussion of enhanced surveillance strategies, including annual whole-body MRI screening. However, specific surveillance protocols for liposarcoma are undefined. Family members of patients with Li-Fraumeni syndrome should be offered genetic testing to assess inherited cancer risk. Patient education following liposarcoma diagnosis should emphasize the importance of adhering to recommended surveillance imaging schedules to enable early detection of recurrence or metastatic disease when treatment options are most effective. Patients should understand that surveillance intensity and duration depend on histologic subtype, grade, anatomic location, and margin status, with high-risk features warranting more frequent monitoring. Well-differentiated liposarcoma patients require long-term surveillance extending beyond 10 years due to the potential for late recurrence, while high-grade subtypes necessitate intensive monitoring during the first 2 to 3 years, when the recurrence risk is highest. Patients with myxoid liposarcoma should be educated regarding unusual metastatic patterns necessitating whole-body surveillance rather than chest imaging alone. Survivors should be counseled to report new symptoms, including enlarging masses, persistent pain, respiratory symptoms, or constitutional symptoms, promptly to their oncology team for evaluation.

Optimal management of liposarcoma requires coordinated interprofessional collaboration at specialized centers for sarcoma care. Primary care clinicians play a critical role in the early recognition and appropriate referral of concerning soft tissue masses. Any deep-seated mass, a superficial mass exceeding 5 cm, a rapidly enlarging mass, or a painful mass should prompt urgent referral to a sarcoma center before biopsy or attempted excision. Inadvertent excision under the presumption of benign lipoma compromises tissue planes, increases local recurrence risk, and may necessitate more extensive re-resection. Radiologists with musculoskeletal imaging expertise provide essential diagnostic evaluation through high-quality MRI for extremity tumors and CT for retroperitoneal disease. Interventional radiologists perform image-guided core needle biopsies with appropriate technique, ensuring biopsy tracts align with planned surgical incisions. Pathologists specializing in soft tissue pathology deliver accurate histologic diagnoses by integrating histomorphology, immunohistochemistry, and molecular diagnostics, including MDM2 amplification testing and fusion gene analysis. Surgical oncologists with sarcoma expertise perform definitive resections using oncologic principles to achieve negative margins while preserving function. Complex cases require collaboration with vascular, plastic, orthopedic, thoracic, urologic, or colorectal surgeons. Radiation oncologists develop treatment plans using modern techniques to optimize tumor coverage while minimizing the toxicity to normal tissue. Medical oncologists guide systemic therapy decisions based on histologic subtype-specific chemosensitivity, manage treatment toxicities, and coordinate enrollment in clinical trials.

Surgical oncologists with sarcoma expertise perform definitive resections using oncologic principles to achieve negative margins while preserving function. Complex cases require collaboration with vascular, plastic, orthopedic, thoracic, urologic, or colorectal surgeons. Radiation oncologists develop treatment plans using modern techniques to optimize tumor coverage while minimizing the toxicity to normal tissue. Medical oncologists guide systemic therapy decisions based on histologic subtype-specific chemosensitivity, manage treatment toxicities, and coordinate enrollment in clinical trials. Specialty-trained oncology nurses coordinate patient care across treatment phases, provide education, manage symptoms, and facilitate communication between patients and the interprofessional team. Oncology nurse navigators guide patients through complex treatment pathways and address psychosocial needs. Physical and occupational therapists help individuals optimize functional recovery through targeted rehabilitation programs. Palliative care specialists provide symptom management and discussions on goals of care for patients with advanced disease. Social workers address financial concerns, transportation needs, and support for caregivers. Regular interprofessional tumor board conferences facilitate the prospective discussion of newly diagnosed patients, review of imaging and pathology, treatment planning, and case coordination. High-volume sarcoma centers with standardized treatment pathways have demonstrated improved survival, reduced local recurrence, and enhanced functional outcomes compared with community hospitals. Interprofessional collaboration, clear communication channels, and patient-centered decision-making optimize clinical outcomes while maintaining quality of life.